NASDAQ:ATRI - Atrion Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$725.01 -2.45 (-0.34 %)
(As of 11/15/2018 01:15 AM ET)
Previous Close$727.46
Today's Range$718.00 - $730.00
52-Week Range$516.85 - $730.00
Volume16,800 shs
Average Volume7,998 shs
Market Capitalization$1.33 billion
P/E Ratio37.98
Dividend Yield0.75%
Beta0.56
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 myocardial protection system that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products that are used in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers, as well as other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Receive ATRI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRI
Previous Symbol
CUSIP04990410
Phone972-390-9800

Debt

Debt-to-Equity RatioN/A
Current Ratio10.10
Quick Ratio7.88

Price-To-Earnings

Trailing P/E Ratio37.98
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.60 million
Price / Sales9.15
Cash Flow$23.4783 per share
Price / Cash30.88
Book Value$110.73 per share
Price / Book6.55

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$36.59 million
Net Margins23.19%
Return on Equity18.01%
Return on Assets16.26%

Miscellaneous

Employees528
Outstanding Shares1,850,000
Market Cap$1.33 billion
OptionableNot Optionable

Atrion (NASDAQ:ATRI) Frequently Asked Questions

What is Atrion's stock symbol?

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

How often does Atrion pay dividends? What is the dividend yield for Atrion?

Atrion declared a quarterly dividend on Monday, November 12th. Shareholders of record on Monday, December 3rd will be paid a dividend of $1.35 per share on Monday, December 17th. This represents a $5.40 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend is Friday, November 30th. View Atrion's Dividend History.

How were Atrion's earnings last quarter?

Atrion Co. (NASDAQ:ATRI) announced its quarterly earnings data on Tuesday, February, 27th. The medical instruments supplier reported $4.66 earnings per share (EPS) for the quarter. The medical instruments supplier earned $34.02 million during the quarter. Atrion had a net margin of 23.19% and a return on equity of 18.01%. View Atrion's Earnings History.

When is Atrion's next earnings date?

Atrion is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Atrion.

Has Atrion been receiving favorable news coverage?

News articles about ATRI stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Atrion earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Atrion's key competitors?

Who are Atrion's key executives?

Atrion's management team includes the folowing people:
  • Mr. Emile A. Battat, Exec. Chairman (Age 80)
  • Mr. David A. Battat, Pres & CEO (Age 48)
  • Mr. Jeffery Strickland, VP, CFO, Sec. & Treasurer (Age 59)

Who are Atrion's major shareholders?

Atrion's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.27%), Renaissance Technologies LLC (3.69%), Cornerstone Wealth Management LLC (3.57%), Thomson Horstmann & Bryant Inc. (0.79%), BTIM Corp. (0.74%) and Crawford Investment Counsel Inc. (0.38%). Company insiders that own Atrion stock include Emile A Battat and Jeffery Strickland. View Institutional Ownership Trends for Atrion.

Which institutional investors are selling Atrion stock?

ATRI stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., JPMorgan Chase & Co., JPMorgan Chase & Co., Renaissance Technologies LLC, BTIM Corp., Citadel Advisors LLC and Credit Suisse AG. View Insider Buying and Selling for Atrion.

Which institutional investors are buying Atrion stock?

ATRI stock was acquired by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Assenagon Asset Management S.A., First Trust Advisors LP, SG Americas Securities LLC, Denali Advisors LLC, Rhumbline Advisers, Schroder Investment Management Group and Crawford Investment Counsel Inc.. View Insider Buying and Selling for Atrion.

How do I buy shares of Atrion?

Shares of ATRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atrion's stock price today?

One share of ATRI stock can currently be purchased for approximately $725.01.

How big of a company is Atrion?

Atrion has a market capitalization of $1.33 billion and generates $146.60 million in revenue each year. Atrion employs 528 workers across the globe.

What is Atrion's official website?

The official website for Atrion is http://www.atrioncorp.com.

How can I contact Atrion?

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The medical instruments supplier can be reached via phone at 972-390-9800 or via email at [email protected]


MarketBeat Community Rating for Atrion (NASDAQ ATRI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Atrion and other stocks. Vote "Outperform" if you believe ATRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Featured Article: Day Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel